BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04146051 (Descartes-08 in Generalized Myasthenia Gravis): BVCT ex-ante prediction vs. reported outcome

On 26 Apr 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 2 Jul 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient superior to efgartigimod.

Clinical Trial

NCTID
NCT04146051
Drug Name
Descartes-08
Drug MoA
autologous anti-BCMA CAR-T therapy
Drug Modality
CAR-T therapy
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
Generalized Myasthenia Gravis
Human Patients
30
Sponsor
Cartesian Therapeutics
Phase
Phase 2b

Prediction of , index 1580

Prospective Prediction
Prediction Index
1580
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit with superior-to-efgartigimod efficacy)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
67 days in advance
Readout Data Interpretation
46% placebo-adjusted >=5 MGC response at week 12 (vs efgartigimod 30% placebo-adjusted >=3 MGC response at week 26 ADAPT trial).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient superior to efgartigimod
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)
Phase
Phase 2
Status
Active not recruiting
Enrollment
30
Lead sponsor
Cartesian Therapeutics
Conditions
Myasthenia Gravis, Generalized
Interventions
DRUG: Descartes-08
Design
Randomized · Crossover · Quadruple
Primary purpose
Treatment
Start
2019-12-04
Primary completion
2026-01-05
Completion
2026-09-30
Primary outcomes
  • Proportion of patients with MG Composite improvement of ≥5 points. (Day 0 to Day 85)

NCT04146051 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials